Every 424B that MAIA Biotechnology, Inc. (MAIA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow MAIA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MAIA filings page.
MAIA Biotechnology, Inc. registered 751,879 shares of common stock for resale by PoC Capital LLC. MAIA will not receive proceeds from PoC’s sales. Separately, PoC agreed to provide $1,000,000 following the prospectus date, to be applied to company expenses for studies evaluating THIO in patients with cancer.
The shares were received under a Clinical Trial Funding Agreement dated August 29, 2026. PoC may sell all, some or none in public or private transactions at prevailing market prices, prices related to prevailing market prices, or privately negotiated prices. MAIA also states that substantial doubt exists regarding its ability to continue as a going concern and that it will need substantial additional funding.
MAIA Biotechnology, Inc. registered 751,879 shares of common stock for resale by PoC Capital, LLC, which received them under a Clinical Trial Funding Agreement. PoC Capital may sell at prevailing market prices, prices related to prevailing market prices or privately negotiated prices; MAIA will receive no proceeds from these resales.
Separately, PoC Capital agreed to provide $1,000,000 in funding following the prospectus date, to be applied to MAIA's expenses for studies evaluating THIO's safety, tolerability, efficacy and pharmacodynamics in cancer patients.
MAIA describes itself as a clinical-stage company developing investigational ateganosine (THIO). Its Phase 3 THIO-104 trial, initiated in 2025, is designed to compare ateganosine sequenced with a checkpoint inhibitor against chemotherapy in a 1:1 randomization of up to 300 third-line NSCLC patients resistant to checkpoint inhibitors and chemotherapy. MAIA also states there is substantial doubt regarding its ability to continue as a going concern and that it needs substantial additional funding, which may not be available on acceptable terms or at all.
MAIA Biotechnology, Inc. is amending its shelf to report termination of its at-the-market program covering up to $11,200,000 of common stock. The company reports that, since the prior prospectus dated March 28, 2025, it sold 3,116,012 shares for gross proceeds of $5,680,924 under the sales agreement with H.C. Wainwright & Co.
On May 14, 2026 MAIA suspended sales under the sales agreement and provided notice to terminate the agreement and the related at-the-market offering; termination becomes effective seven business days after May 14, 2026. The supplement also terminates the prior prospectuses on the same schedule. The last reported sale price on the NYSE American was $1.36 per share on May 14, 2026.
MAIA Biotechnology, Inc. is offering 20,000,000 shares of common stock at a public offering price of $1.50 per share.
The offering includes a 30-day option for the underwriters to purchase up to 3,000,000 additional shares. The underwriters expect to deliver the shares on or about March 4, 2026. Estimated net proceeds to the company are approximately $28.0 million, or approximately $32.3 million if the over-allotment option is fully exercised. The prospectus supplement bases post-offering outstanding shares on 38,659,579 shares as of March 2, 2026.
MAIA Biotechnology, Inc. is offering shares of its common stock and pre-funded warrants pursuant to a shelf prospectus supplement dated March 2, 2026. The pre-funded warrants are offered to purchasers who would otherwise exceed 4.99% (or, at the election of the purchaser, 9.99%) beneficial ownership post-offering. Each pre-funded warrant is exercisable for one share at an exercise price of $0.0001 and will be immediately exercisable. The prospectus references the company’s NYSE American listing under the symbol MAIA and reports 38,659,579 shares outstanding as of March 2, 2026 in the offering context. The document discloses underwriting arrangements, a 30-day 15% overallotment option, intended use of proceeds for clinical trials and working capital, and risk factors regarding dilution, liquidity for pre-funded warrants, and the company’s financing needs.